Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride

Author(s):  Zur Eyal

Issue:  Sep/Oct 2011 - Volume 15, Number 5
View All Articles in Issue

Page(s):  358-366

Note:  Electronic version includes supplemental material.

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 1
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 2
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 3
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 4
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 5
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 6
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 7
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 8
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride Page 9

Download in electronic PDF format for $75

Abstract:  Infantile hemangiomas are the most common benign tumors of infancy. Although a well-known pathology with substantial medical experience, the etiology and pathogenesis of this disease is not exactly known. In most cases, the pathology regresses spontaneously around the age of 12 months without complications and without the need of medical treatment. However, sometimes the complications are severe and even life threatening, and medical intervention is mandatory. Until 2008, the first-line treatment of this pathology was primarily oral and topical corticosteroids, with suboptimal results and unpleasant side effects. The serendipitous discovery of the unusual effect of oral propranolol hydrochloride on infantile hemangiomas, causes a mini-revolution in the pediatric dermatology society world wide. Propranolol hydrochloride not only stopped the proliferative phase of the tumor but also resulted in a remarkable shrinkage and substantial improvement in the clinical parameters of the tumor, including life-threatening complications, with minimal side effects. In this article, the compounding pharmacist can learn comprehensively about this pathology, and about the current accumulative knowledge in the treatment of oral propranolol hydrochloride. Topical treatment with the use of beta blockers in the treatment of infantile hemangiomas is discussed in Part 2 of this article.

Related Keywords: Eyal Zur, RPh, MBA, infants, children, formulation, benign vascular tumor, propranolol hydrochloride, beta blocker, complications, skin disorders, PHACE syndrome, risk factors, adverse effects, angiogenesis, blood vessels, vasculogenesis, endothelial progenitor cell proliferation, lymphangioma, intractable diffuse lymphangiomatosis

Related Categories: DERMATOLOGY, FORMULATIONS, PEDIATRICS, CARDIOLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Zur Eyal
Sep/Oct 2011
Pg. 358-366

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
Jul/Aug 2018
Pg. 325

Propranolol Hydrochloride 1-mg/mL Oral Liquid
Allen Loyd V Jr
Jul/Aug 2006
Pg. 304

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M
, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2012
Pg. 513-515

Propranolol Hydrochloride 1-mg/mL Injection
Allen Loyd V Jr
Jul/Aug 2014
Pg. 330

Propranolol Hydrochloride Capsules
Allen Loyd V Jr
Nov/Dec 2015
Pg. 513

Simple Preparation of Timolol 0.5% Gel from Eye Drop Solution for Superficial Infantile Hemangiomas
Choo Winnie
Jul/Aug 2017
Pg. 282-289

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Quantitation of Metoprolol Tartrate and Propranolol Hydrochloride in Pharmaceutical Dosage Forms: Stability of Metoprolol in an Aqueous Mixture
Gupta Vishnu D
, Maswoswe J
Mar/Apr 1997
Pg. 125-127

Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet
Allen Loyd V Jr
Nov/Dec 2021
Pg. 504

Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension
Allen Loyd V Jr
Mar/Apr 2022
Pg. 148

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

Topical Cholesterol/Simvastatin Gel for the Treatment of CHILD Syndrome in an Adolescent
Cho Sung Kyung
, Ashworth Lisa Diggs, Goldman Shauna
Sep/Oct 2020
Pg. 367-369

Transdermals: The Skin as Part of a Drug Delivery System
Allen Loyd V Jr
Jul/Aug 2011
Pg. 308-315

Basics of Compounding for Dry-Skin Conditions
Allen Loyd V Jr
Nov/Dec 2003
Pg. 460-463

View Sample
Return to Top